Home » Market News » DirectorsTalk Highlights » Long Island startup to test COVID-19 vaccine on humans
Open Orphan PLC

Long Island startup to test COVID-19 vaccine on humans

A tiny Long Island biotechnology startup in a global race to develop a COVID-19 vaccine has rolled out plans for a human trial.

The Phase 1 trial using about 50 paid young adult volunteers will evaluate the safety of the Codagenix Inc. vaccine and will be conducted in London by a unit of Dublin-based Open Orphan plc. 

Codagenix Inc.’s vaccine is made from a live, but attenuated — or weakened — version of the whole virus that is re-engineered to slow its ability to make copies of itself.

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.